(8-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone

ID: ALA5083820

Chembl Id: CHEMBL5083820

PubChem CID: 129080680

Max Phase: Preclinical

Molecular Formula: C25H27F4N5O2

Molecular Weight: 505.52

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C(C1CCN(CC(F)(F)F)CC1)N1Cc2cc(F)cnc2Nc2ccc(N3C[C@@H]4C[C@H]3CO4)cc21

Standard InChI:  InChI=1S/C25H27F4N5O2/c26-17-7-16-11-34(24(35)15-3-5-32(6-4-15)14-25(27,28)29)22-9-18(33-12-20-8-19(33)13-36-20)1-2-21(22)31-23(16)30-10-17/h1-2,7,9-10,15,19-20H,3-6,8,11-14H2,(H,30,31)/t19-,20-/m0/s1

Standard InChI Key:  COJUCQAWOGIMSE-PMACEKPBSA-N

Alternative Forms

  1. Parent:

    ALA5083820

    ---

Associated Targets(Human)

IDH1 Tclin Isocitrate dehydrogenase [NADP] cytoplasmic (40980 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MOG-G-UVW (38 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ABCB1 Tchem P-glycoprotein 1 (14716 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 505.52Molecular Weight (Monoisotopic): 505.2101AlogP: 4.06#Rotatable Bonds: 3
Polar Surface Area: 60.94Molecular Species: NEUTRALHBA: 6HBD: 1
#RO5 Violations: 1HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski): 1
CX Acidic pKa: 12.29CX Basic pKa: 3.85CX LogP: 3.12CX LogD: 3.12
Aromatic Rings: 2Heavy Atoms: 36QED Weighted: 0.64Np Likeness Score: -0.95

References

1. Huang C, Fischer C, Machacek MR, Bogen S, Biftu T, Huang X, Reutershan MH, Otte R, Hong Q, Wu Z, Yu Y, Park M, Chen L, Biju P, Knemeyer I, Lu P, Kochansky CJ, Hicks MB, Liu Y, Helmy R, Fradera X, Donofrio A, Close J, Maddess ML, White C, Sloman DL, Sciammetta N, Lu J, Gibeau C, Simov V, Zhang H, Fuller P, Witter D..  (2022)  Diminishing GSH-Adduct Formation of Tricyclic Diazepine-based Mutant IDH1 Inhibitors.,  13  (4.0): [PMID:35450359] [10.1021/acsmedchemlett.2c00089]

Source